Disclosures: Rosa Lombardi: Nothing to Disclose, Roberta Forlano: Nothing to Disclose, Annalisa Cespiati: Nothing to Disclose, Felice Cinque: Nothing to Disclose, Gabriele Maffi: Nothing to Disclose, Paola Dongiovanni: Nothing to Disclose, Daniela Bignamini: Nothing to Disclose, Paolo Francione: Nothing to Disclose, Giordano Sigon: Nothing to Disclose, Jian Huang: Nothing to Disclose, Pinelopi Manousou: Nothing to Disclose, Flora Peyvandi: Nothing to Disclose, Armando Tripodi: Nothing to Disclose, Anna Fracanzani: Nothing to Disclose 609 ANALYSIS OF CARDIOVASCULAR RISK FACTORS DURING THE TREATMENT OF METABOLIC DYSFUNCTION ASSOCIATED FATTY LIVER DISEASE WITH A LOW CARBOHYDRATE DIET Kwan Kit Cheung 1 Hongbo Du 1 , 1 Dongzhimen Hospital, Beijing University of Chinese Medicine Background: This study aimed to analyze cardiovascular risk factors during the treatment of metabolic dysfunction-associated fatty liver disease (MAFLD) with a low-carbohydrate diet
10.1038/nrm3801 39 HongS.HuhJ
Biomimetics 8 (8), 592 (2023)
While research suggests potential advantages, its equally important to acknowledge the limited data on long-term effects in humans and the FDAs categorization of ipamorelin as a 503A/503B drug
Cancer Cell 27, 211222
Atlantas role as a Southeastern medical-tourism anchor means many patients travel from neighboring states making 503B sourcing (broader shipping options) more relevant than in self-contained metros
